New factories will be built in the United States over the next five years and will create 3,000 jobs for skilled workers.
Eli Lilly plans to spend at least 27 billion dollars to build four new manufacturing factories in the United States, said the drug manufacturer while climbing with the threat of drug import tasks from the Trump administration.
The new factories will be built over the next five years and are expected to create more than 3,000 jobs for skilled workers such as engineers and scientists as well as 10,000 construction jobs, the company announced at a press conference in Washington on Wednesday.
Lilly said that she will announce the sites of the sites later this year.
The announcement comes less than a week after US President Donald Trump met with heads of the management of major drug manufacturers, including the CEO of Lilly, David Ricks, to discuss industry concerns such as prices on drug imports.
The US Secretary of Commerce Howard Lutnick said at the press conference that Lilly did “exactly what the president hoped to happen”.
Ricks said he hoped that the government would free up medical supplies from potential prices and continue to continue new tax reforms.
The CEO said in a statement earlier on Wednesday that the tax cutting legislation introduced during Trump’s first mandate was fundamental to the interior investments in the manufacturer of the drug manufacturer.
Boost interior manufacturing
Trump, who campaigned on a promise to stimulate domestic manufacturing, has been pressure on drug manufacturers since he took office to move the production of medicines in the United States. He suggested last week that he could impose a 25% right on pharmaceutical products and other imports.
Other sectors also make manufacturing announcements. Earlier this week, Apple said that it would spend $ 500 billion in the United States in the next four years, but analysts have declared that some of them included current commitments.
The United States and its main business partners have agreed to eliminate reciprocal prices for pharmaceutical products and chemicals used in the production of drugs over the past 30 years, according to the office of the American commercial representative.
Although he said to the Republicans at a White House meeting earlier this month that he was considering such an exemption, Trump has not yet excluded.
Answering a question about federal employee dismissals at Food and Drug Administration of the United States, the CEO said Lilly’s fees were going to finance agency staff and that the company would be concerned if these funds “were directed towards something else”.
Lilly, who has become the most precious health company in the world, worth more than $ 855 billion, said that she had already started $ 23 billion to increase her American manufacturing footprint since 2020. Her announcement on Wednesday has been totaling more than $ 50 billion.
Three of the new Lilly plants will be used to make gross pharmaceutical ingredients, while the fourth will make injection medications, said the drug manufacturer.
